This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year?
by Zacks Equity Research
Here is how Amneal Pharmaceuticals (AMRX) and KalVista Pharmaceuticals, Inc. (KALV) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Cabaletta Bio (CABA) This Year?
by Zacks Equity Research
Here is how Cabaletta Bio, Inc. (CABA) and KalVista Pharmaceuticals, Inc. (KALV) have performed compared to their sector so far this year.
Is it a Good Idea to Invest in KalVista (KALV) Stock Now?
by Zacks Equity Research
Here we discuss some reasons why investing in KalVista Pharmaceuticals (KALV) stock now may turn out to be a prudent move now.
Here's Why You Should Invest in Alpine (ALPN) Stock Now
by Zacks Equity Research
Alpine (ALPN) plans to begin a broad and accelerated development program for povetacicept across multiple indications in 2024.
Zacks Industry Outlook Highlights Corcept Therapeutics, Aurinia Pharmaceuticals, Alpine Immune Sciences, KalVista Pharmaceuticals and Cardiol Therapeutics
by Zacks Equity Research
Corcept Therapeutics, Aurinia Pharmaceuticals, Alpine Immune Sciences, KalVista Pharmaceuticals and Cardiol Therapeutics are part of the Zacks Industry Outlook article.
5 Stocks to Buy as Drug Industry Displays Strong Fundamentals
by Kinjel Shah
Innovation is expected to continue driving growth in the Medical-Drugs industry. CORT, AUPH, ALPN, KALV and CRDL may prove to be good additions to one's portfolio.
Is KalVista Pharmaceuticals (KALV) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how KalVista Pharmaceuticals, Inc. (KALV) and Achilles Therapeutics PLC Sponsored ADR (ACHL) have performed compared to their sector so far this year.
KalVista (KALV) Surges 15% on Update From Angioedema Study
by Zacks Equity Research
KalVista (KALV) announces a positive update from its late-stage study on its lead product candidate, sebetralstat, in the treatment of hereditary angioedema attacks. The stock rises 15% in response.
Wall Street Analysts See a 145.38% Upside in KalVista Pharmaceuticals, Inc. (KALV): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 145.4% upside potential for KalVista Pharmaceuticals, Inc. (KALV). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Here's Why You Should Invest in Larimar (LRMR) Stock Now
by Zacks Equity Research
Here we discuss some reasons why investing in Larimar Therapeutics (LRMR) stock now is a good idea.
Here's Why You Can Add KalVista (KALV) Stock to Your Portfolio
by Zacks Equity Research
Here we discuss some reasons why investing in KalVista Pharmaceuticals (KALV) stock now is a good idea.
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar Therapeutics, Nektar Therapeutics and Jounce Therapeutics
by Zacks Equity Research
Catalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar Therapeutics, Nektar Therapeutics and Jounce Therapeutics are part of the Zacks Industry Outlook article.
5 Stocks to Buy as the Drug Industry Rebounds in 2023
by Kinjel Shah
Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. CPRX, KALV, LRMR, NKTR, JNCE may prove to be good additions to one's portfolio.
Wall Street Analysts Think KalVista Pharmaceuticals, Inc. (KALV) Could Surge 145.98%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 146% upside potential for KalVista Pharmaceuticals, Inc. (KALV). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
KalVista Pharmaceuticals, Inc. (KALV) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
KalVista Pharmaceuticals, Inc. (KALV) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Wall Street Analysts See a 155.32% Upside in KalVista Pharmaceuticals, Inc. (KALV): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for KalVista Pharmaceuticals, Inc. (KALV) points to a 155.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
What Makes KalVista Pharmaceuticals, Inc. (KALV) a New Buy Stock
by Zacks Equity Research
KalVista Pharmaceuticals, Inc. (KALV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Think KalVista Pharmaceuticals, Inc. (KALV) Could Surge 149.94%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for KalVista Pharmaceuticals, Inc. (KALV) points to a 149.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Will Pacira's (PCRX) Exparel Aid Growth Amid High Reliance?
by Zacks Equity Research
Pacira's (PCRX) flagship product Exparel, along with other marketed products, is driving year over year growth. Pacira's efforts to expand Exparel label also holds promise.
KalVista (KALV) Stock Continues to Decline: Here's Why
by Zacks Equity Research
The recent setback faced by KalVista (KALV) for terminating the phase II KOMPLETE study evaluating KVD824 for prophylactic treatment of hereditary angioedema hurts the stock.
Biotech Stock Roundup: ICPT, KALV Down on Study Data, VIR Up on Contract Win & More
by Zacks Equity Research
Regulatory and pipeline updates from ICPT and KALV are the key highlights from the biotech sector during the past week.
Analysts Estimate KalVista Pharmaceuticals, Inc. (KALV) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
KalVista Pharmaceuticals, Inc. (KALV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
KalVista Pharmaceuticals, Inc. (KALV) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
KalVista Pharmaceuticals, Inc. (KALV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
KalVista Pharmaceuticals, Inc. (KALV) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
KalVista Pharmaceuticals, Inc. (KALV) delivered earnings and revenue surprises of 6.67% and -100.00%, respectively, for the quarter ended January 2021. Do the numbers hold clues to what lies ahead for the stock?
KalVista Pharmaceuticals, Inc. (KALV) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
KalVista Pharmaceuticals, Inc. (KALV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.